CXCR4 and acute graft versus host disease: Plerixafor, a small molecule inhibitor of CXCR4, has exhibited good efficacy in mobilizing hematopoietic stem cells from donors, accompanied by a lower incidence of acute GVHD and cytomegalovirus (CMV) viremia (92, 93).